Endometrial Cancer News and Research

RSS

Researchers examine risk of four common types of ovarian cancer in women with different childbearing patterns

The more children a woman has or whether a woman has had her fallopian tubes cut lowers the risk of different types of ovarian cancer to different levels, according to new research presented at the 2015 National Cancer Research Institute Cancer Conference today (Tuesday).

3 Nov 2015

Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on identifying women who are candidates for treatment of menopausal symptoms and selecting the best treatment options for each individual.

8 Oct 2015

Survey: One-third of US women use compounded hormones at menopause

A third of US women who take hormones at menopause are using compounded hormones, shows a new national survey. These women commonly--and mistakenly--think these hormones are safer and offer more benefits than FDA-approved therapies.

30 Sep 2015

PharmaMar begins phase II 'Basket' trial to evaluate safety, efficacy of PM1183 in advanced solid tumors

PharmaMar announced today the start of a multicenter, international, open-label, exploratory phase II "Basket" trial (NCT02454972) to evaluate the efficacy and safety of the anticancer agent PM1183 (lurbinectedin) in advanced solid tumors.

18 Sep 2015

New AGA guideline recommends colorectal cancer patients to undergo tumor test for Lynch syndrome

All colorectal cancer patients should undergo tumor testing to see if they carry Lynch syndrome, the most common inherited cause of colorectal cancer, according to a new guideline published in Gastroenterology, the official journal of the American Gastroenterological Association.

11 Sep 2015

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance Pharmaceuticals Inc. today announced that it has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer candidate EP-100 for the treatment of ovarian cancer and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer.

24 Aug 2015

Aeterna Zentaris reports that DSMB scheduled to close second interim analysis of ZoptEC Phase 3 trial in early October

Aeterna Zentaris Inc. today announced that the independent Data and Safety Monitoring Board for the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer, will complete a pre-specified second interim efficacy and safety analysis of the compound in early October 2015.

11 Aug 2015

Meta-analysis confirms oral contraceptives reduce endometrial cancer risk

Oral contraceptive use protects against endometrial cancer, with effects persisting for decades after cessation of use, shows a meta-analysis of individual patient data published in The Lancet Oncology.

10 Aug 2015

Oral contraceptives give long-term protection against endometrial cancer, shows study

Use of oral contraceptives, even for just a few years, gives substantial long-term protection against endometrial cancer, and the longer the pill is used the greater the reduction in risk, according to a detailed re-analysis of all the available evidence, published in The Lancet Oncology journal.

5 Aug 2015

Researchers identify link between hormonal factors and endometrial cancer risk among women with Lynch syndrome

For women with Lynch syndrome, an association was found between the risk of endometrial cancer and the age of first menstrual cycle, having given birth, and hormonal contraceptive use, according to a study in the July 7 issue of JAMA. Lynch syndrome is a genetic condition that increases the risk for various cancers.

8 Jul 2015

Study: Extended-field IMRT for cervical or endometrial cancer does not increase risk of duodenal toxicity

A study of women with cervical or endometrial cancer who require treatment to the para-aortic (PA) lymph nodes can safely receive extended-field intensity modulated radiation therapy (EF-IMRT) without increased risk of duodenal toxicity, according to a study published in the July-August 2015 issue of Practical Radiation Oncology, the American Society for Radiation Oncology's journal focused on the clinical practice of radiation oncology.

8 Jul 2015

Aeterna Zentaris recruits patients for ZoptEC Phase 3 study in women with advanced endometrial cancer

Aeterna Zentaris Inc. today announced it has reached its goal of recruiting 500 patients for its pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) clinical study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer.

30 Jun 2015

Aeterna Zentaris selects Ergomed to manage Phase 3 clinical study of Macrilen

Aeterna Zentaris Inc. announced today that it has executed a definitive agreement with Ergomed PLC, pursuant to which Ergomed will manage the new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ("AGHD").

25 Jun 2015

Study: Nut consumption associated with decreased risk of some types of cancer, but not type 2 diabetes

Cancer and type 2 diabetes are two of the most significant public health burdens facing the world today, and currently available data suggests their prevalence is expected to continue to increase. Nut consumption has long been hypothesized to have a role in preventing both of these diseases, but until now evidence has been inconsistent.

17 Jun 2015

Nanoplatform technology that detects early stages of cancer receives U.S. patent

A U.S. patent has been awarded to a Kansas State University technology that quickly detects the early stages of cancer before physical symptoms ever appear.

17 Jun 2015

Certain ARID1a mutations sensitize some tumors to PARP inhibitor drugs

Mutations in ARID1a, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. This gene may also be an Achilles' heel when treating certain tumors, according to a team of researchers at The University of Texas MD Anderson Cancer Center.

12 Jun 2015

Mistakes in mismatch repair genes may accurately predict response to certain immunotherapy drugs

In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in so-called mismatch repair genes, first identified by Johns Hopkins and other scientists two decades ago, may accurately predict who will respond to certain immunotherapy drugs known as PD-1 inhibitors. Such drugs aim to disarm systems developed by cancer cells to evade detection and destruction by immune system cells.

30 May 2015

Myriad Genetics to highlight new clinical studies on myRisk Hereditary Cancer test at ASCO 2015

Myriad Genetics, Inc. today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.

30 May 2015

Mediterranean-style diet can reduce womb cancer risk by half

Women who eat a Mediterranean diet could cut their risk of womb cancer by more than half (57 per cent), according to a study published today (Wednesday) in the British Journal of Cancer.

27 May 2015

Smoking-related DNA damage can be detected in cheek swabs

DNA damage caused by smoking can be detected in cheek swabs, finds research published today in JAMA Oncology. The study provides evidence that smoking induces a general cancer program that is also present in cancers which aren't usually associated with it - including breast and gynaecological cancers.

15 May 2015